




RealRate

# PHARMACEUTICAL 2020

Atossa Therapeutics INC  
Rank 160 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Atossa Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atossa Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 118% points. The greatest weakness of Atossa Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 26% points above the market average of 238%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 14,319               |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 69                   |
| Liabilities, Current                        | 1,323                |
| Liabilities, Non-Current                    | 11                   |
| Other Assets                                | 68                   |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 0                    |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 26                   |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 34                   |
| Research and Development                    | 6,645                |
| Selling, General and Administrative Expense | 10,620               |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 14,490               |
| Liabilities                 | 1,334                |
| Expenses                    | 17,265               |
| Revenues                    | 0                    |
| Stockholders Equity         | 13,156               |
| Net Income                  | -17,240              |
| Comprehensive Net Income    | -17,240              |
| BaseVar                     | 16,557               |
| ECR before LimitedLiability | 145%                 |
| Economic Capital Ratio      | 264%                 |